Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report

Authors: Orion Valet, Aurélie Swalduz, MD, Maxime Boussageon, MD, Adrien Buisson, Virginie Avrillon, MD, Bénédicte Mastroïanni, MD, Maurice Pérol, MD

Source: JTO Clinical and Research Reports, Vol 2, Iss 6, Pp 100192- (2021)

Subject Terms: Case report, EGFR mechanism of resistance, BRAF mutation, Dabrafenib-trametinib combination, Leptomeningeal disease, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364321000515; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/7b39d599ea7647109b747e84117b2f10